Psoriasis

The Psoriasis pipeline: 113 tracked drugs, 48 approved for this indication.

48 approved / phase 427 Phase 33 Phase 2/321 Phase 22 Phase 1/29 Phase 13 preclinical / unstaged

Compare the share prices of listed companies in Psoriasis →

Total attributable cost

$28.4B

$3,592/patient

Drug spend

Not yet sourced

How this is calculated ↗

All severities, physician-diagnosed history (2023 NHIS) · US

The Psoriasis pipeline

Key trial results for every approved and late-stage drug: Psoriasis results by drug.

← all assets